Methods and kits for analyzing nucleosomes and plasma proteins

Patent metadata

Field	Value
Publication number	US-2024352538-A1
Application number	US-202418764250-A
Country	US
Kind code	A1
Filing date	Jul 4, 2024
Priority date	Jan 5, 2022
Publication date	Oct 24, 2024
Grant date	—

Abstract

A method of analyzing nucleosomes is provided. The method comprising: (a) isolating a plurality of nucleosome molecules from a biological sample; (b) enzymatically linking adenine nucleotides to free DNA ends of the plurality of nucleosome molecules, wherein at least a portion of the adenine nucleotides comprises a label, such that the plurality of nucleosome molecules become attached to a labeled poly(A) tail; (c) hybridizing the plurality of nucleosome molecules attached to the labeled poly(A) tail to a solid support coated with poly(T); and (d) imaging the solid support, whereby the plurality of nucleosome molecules are visualized.

First claim

What is claimed is:

1 . A method of analyzing nucleosomes, the method comprising:
(a) isolating a plurality of nucleosome molecules from a biological sample; (b) enzymatically linking adenine nucleotides to free DNA ends of said plurality of nucleosome molecules, wherein at least a portion of said adenine nucleotides comprises a label, such that said plurality of nucleosome molecules become attached to a labeled poly(A) tail; (c) hybridizing said plurality of nucleosome molecules attached to said labeled poly(A) tail to a solid support coated with poly(T); and (d) imaging said solid support, whereby said plurality of nucleosome molecules are visualized.

2 . The method of claim 1 , further comprising:
(e) incubating said solid support with at least one labeling ligand with specific binding affinity for a target molecule of said nucleosome and wherein the labeling ligand includes a marker; (f) imaging the solid support, whereby said plurality of nucleosome molecules comprising said target molecule are visualized.

3 . The method of claim 1 , wherein said enzymatically linking comprises using a template-dependent DNA polymerase and a Terminal deoxynucleotidyl transferase (TdT).

4 . The method of claim 3 , wherein said template-dependent DNA polymerase comprises a Klenow polymerase.

5 . The method of claim 1 , wherein said biological sample comprises a biological fluid, optionally plasma, optionally said plasma is less than 1 ml.

6 . The method of claim 2 , further comprising cleaving said label and optionally washing it prior to step (e).

7 . The method of claim 2 , wherein said labeling ligand comprises an antibody.

8 . The method of claim 2 , wherein said target molecule is a post translational modification.

9 . The method of claim 2 , wherein said target molecule is a histone modification and/or a histone variant optionally said histone variant is selected from the group consisting of macroH2A1.1, macroH2A1.2, H2AZ, H2AX, H3.1 and H3.3.

10 . The method of claim 2 , wherein said target molecule is a nucleotide modification, optionally said nucleotide modification is selected from the group consisting of 5-methyl-(5-mC), 5-hydroxymethyl-(5-hmC), 5-formyl-(5-fC) and 5-carboxy-(5-eaC) cytosine.

11 . The method of claim 2 , wherein said imaging of step (f) comprises time lapse imaging, and/or said imaging of step (f) and optionally (d) comprises TIRF microscopy.

12 . The method of claim 2 , further comprising repeating steps (e) and (f) with additional labeling ligand distinctive of said labeling ligand such as in binding a different target molecule of said nucleosome.

13 . The method of claim 2 , wherein said imaging of step (e) comprises multiplex imaging.

14 . The method of claim 1 , wherein said plurality of nucleosome molecules comprise cell-free nucleosomes (cfNucleosomes).

15 . The method of claim 1 , wherein said solid support is coated with poly ethylene glycol (PEG).

16 . The method of claim 1 , further comprising sequencing DNA of said plurality of nucleosome molecules and optionally wherein said sequencing comprises sequencing by synthesis.

17 . A method of diagnosing a disease associated with modified, cell-free nucleosomes (cfNucleosomes) comprising analyzing nucleosome molecules in a biological fluid according to claim 1 , wherein presence of a pathological nucleorise phenotype is indicative of a disease associated with modified cfNucleosomes.

18 . The method of claim 1 , wherein said phenotype is selected from the group consisting of:
(i) increased concentration of nucleosomes as compared to same in a non-cancerous biological fluid; (ii) altered percentage of modified nucleosome in a specific target molecule in the biological fluid as compared to same in a non-cancerous biological fluid; (iii) altered ratio between a plurality of said target molecules as compared to same in a non-cancerous biological fluid; (iv) altered percentage of nucleosomes that comprise a combinatorial pattern of target molecules in a single nucleosome as compared to same in a biological fluid of a non-cancerous biological fluid.

19 . A method of treating a subject diagnosed with a disease associated with modified, cell-free nucleosomes (cfNucleosomes) in a subject, the method comprising:
(a) affirming diagnosis of the disease according to the method of claim 17 ; (b) administering a treatment to the disease.

20 . A method of analyzing a liquid biological sample, the method comprising analyzing nucleosomes and a protein of interest according to the method of claim 1 .

Assignees

• Yeda Res & Dev
• Seqll Inc

Inventors

• Shema-Yaacoby Efrat
• Nir Erez
• Fedyuk Vadim
• Andreishcheva Ekaterina
• Jones Daniel
• Shinde Abhijeet

Classifications

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q1/6804

  Nucleic acid analysis using immunogens (immunoassay G01N33/53) · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q1/6827

  for detection of mutation or polymorphism · CPC title

• C12Q2521/131

  Terminal transferase · CPC title